Cryolife Inc  

(Public, NYSE:CRY)   Watch this stock  
Find more results for ASHLEY M. CAPPS�
10.13
-0.05 (-0.49%)
Real-time:   9:48AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 10.13 - 10.21
52 week 8.40 - 12.29
Open 10.21
Vol / Avg. 1,623.00/103,334.00
Mkt cap 299.52M
P/E 39.98
Div/yield 0.03/1.18
EPS 0.25
Shares 28.21M
Beta 1.09
Inst. own 58%
May 20, 2015
CryoLife Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Apr 28, 2015
Q1 2015 CryoLife Inc Earnings Call - 10:00AM EDT - Add to calendar
Apr 28, 2015
Q1 2015 CryoLife Inc Earnings Release - 9:30AM EDT - Add to calendar
Feb 17, 2015
Q4 2014 CryoLife Inc Earnings Release
Feb 17, 2015
Q4 2014 CryoLife Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 4.78% 5.06%
Operating margin 5.13% 6.11%
EBITD margin - 10.28%
Return on average assets 4.06% 4.17%
Return on average equity 4.69% 4.88%
Employees 535 -
CDP Score - -

Address

STE 142, 1655 ROBERTS BOULEVARD N W
KENNESAW, GA 30144
United States - Map
+1-770-4193355 (Phone)
+1-770-4260031 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CryoLife, Inc. (CryoLife) develops, manufactures and commercializes medical devices for cardiac and vascular applications and preserves and distributes human tissues for transplantation. The Company operates in two segments, including Medical Devices and Preservation Services. The Medical Devices segment includes revenues from product sales of BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), PerClot, revascularization technologies, HeRO Graft, and other products. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular tissues. The Company�s surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, a powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI).

Officers and directors

James Patrick Mackin Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
D. Ashley Lee CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
David P. Lang Senior Vice President - International Sales and Marketing
Age: 67
Bio & Compensation  - Reuters
Jean F. Holloway Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Bruce G. Anderson Vice President - U.S. Sales and Marketing
Age: 47
Bio & Compensation  - Reuters
Scott B. Capps Vice President - Clinical Research
Age: 47
Bio & Compensation  - Reuters
David M. Fronk Vice President - Regulatory Affairs and Quality Assurance
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David C. Gale Ph.D. Vice President - Research & Development
Age: 46
Bio & Compensation  - Reuters
Jon W. Salveson Director
Age: 49
Bio & Compensation  - Reuters
Thomas F. Ackerman Independent Director
Age: 60
Bio & Compensation  - Reuters